Postmarketing Surveillance Will Report To Deputy Galson Under CDER Reorg.

FDA's Office of Postmarketing Drug Risk Assessment will be transferred out of the Office of Review Management to report directly to CDER Deputy Steven Galson, MD, under a reorganization proposal.